https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30530 Wed 22 Aug 2018 18:00:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:6943 Wed 11 Apr 2018 18:38:10 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21269 Wed 11 Apr 2018 14:00:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44248 U-test) were used to explore associations between responses and previous experience with medicines. Key findings: The most important factors when purchasing NPMs were effectiveness and safety. However, personal experience was the most common method of determining effectiveness. Most respondents believed buying NPMs in pharmacies gave access to advice, but were less likely to agree that pharmacies were associated with safe and effective treatments. Around half the respondents agreed that it is wrong to sell treatments lacking scientific evidence; many also agreed that it is up to consumers to decide what they want even without scientific evidence. Individuals experiencing an ineffective NPM were less likely to trust scientific evidence of efficacy as the sole source of effectiveness information; regular prescription medicine users often agreed that scientific evidence is needed to support effectiveness. Conclusions: Consumers have conflicting views regarding the need for scientific evidence and the desire for patient autonomy in NPM purchases. This presents a challenge for pharmacists wishing to maintain professional obligations to provide evidence-based treatments to consumers.]]> Tue 11 Oct 2022 12:14:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39120 n = 4) while no reason was given in four studies. Seven studies reported that through screening, pharmacists could identify adults with undiagnosed depression. Pharmacists referred adults screening positive for assessment in seven studies and followed up participants in two studies. No study assessed the impact of screening on depressive symptoms or the cost-effectiveness of pharmacists screening for depression. Conclusion: Community pharmacists are able to use depression screening tools to identify undiagnosed adults having symptoms of depression. However, there is little evidence around the impact of this screening on clinical and economic outcomes. Larger, well-designed studies that use a highly accurate, easily administered screening tool and include patient referral and follow-up and pharmacist training are warranted to provide evidence on the impact of community pharmacists screening adults for depression.]]> Tue 10 May 2022 17:14:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:3028 Sat 24 Mar 2018 08:30:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10039 Sat 24 Mar 2018 08:12:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10038 Sat 24 Mar 2018 08:12:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49541 Mon 22 May 2023 08:45:28 AEST ]]>